A U.S. judge ruled on Thursday that Actavis must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.
U.S. judge rules Actavis must continue to sell Alzheimer's drug
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.